Found: 5
Select item for more details and to access through your institution.
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e249, doi. 10.1016/j.clml.2019.09.412
- By:
- Publication type:
- Article
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18).
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 183, n. 2, p. 419, doi. 10.1007/s10549-020-05755-7
- By:
- Publication type:
- Article
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 11, p. 5148, doi. 10.1002/cam4.2425
- By:
- Publication type:
- Article
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. N.PAG, doi. 10.1038/s41467-020-19494-2
- By:
- Publication type:
- Article
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
- Published in:
- 2016
- By:
- Publication type:
- journal article